Potential conflict of interest: Dr. Matsui is on the speakers' bureau for Bayer.
Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma
Version of Record online: 29 SEP 2014
© 2014 by the American Association for the Study of Liver Diseases
Volume 60, Issue 5, pages 1674–1685, November 2014
How to Cite
Yamashita, T., Kitao, A., Matsui, O., Hayashi, T., Nio, K., Kondo, M., Ohno, N., Miyati, T., Okada, H., Yamashita, T., Mizukoshi, E., Honda, M., Nakanuma, Y., Takamura, H., Ohta, T., Nakamoto, Y., Yamamoto, M., Takayama, T., Arii, S., Wang, X. and Kaneko, S. (2014), Gd-EOB-DTPA-enhanced magnetic resonance imaging and alpha-fetoprotein predict prognosis of early-stage hepatocellular carcinoma. Hepatology, 60: 1674–1685. doi: 10.1002/hep.27093
Supported by Health and Labor Sciences Research Grants for “Development of novel molecular markers and imaging modalities for earlier diagnosis of hepatocellular carcinoma,” Grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, the National Cancer Center Research and Development Fund (23-B-5), and the Intramural Research Program Grant (Z01 BC 010313) of the Center for Cancer Research, US National Cancer Institute.
- Issue online: 23 OCT 2014
- Version of Record online: 29 SEP 2014
- Accepted manuscript online: 23 FEB 2014 03:29AM EST
- Manuscript Accepted: 20 FEB 2014
- Manuscript Received: 19 SEP 2013
Additional Supporting Information may be found in the online version of this article at the publisher's website.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.